| Recruiting | Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T- NCT07137416 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Col NCT06626256 | City of Hope Medical Center | Phase 1 |
| Recruiting | MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid Cancers NCT06911008 | Mayo Clinic | Phase 1 |
| Recruiting | TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, NCT07189195 | University of California, Davis | Phase 1 |
| Recruiting | Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in P NCT06364410 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid NCT05687136 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for NCT05803382 | National Cancer Institute (NCI) | Phase 1 |
| Suspended | Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Trea NCT05554380 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Ad NCT05372640 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alteratio NCT05687110 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumo NCT05564377 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advance NCT05327010 | National Cancer Institute (NCI) | Phase 2 |
| Suspended | Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers NCT05372614 | National Cancer Institute (NCI) | Phase 1 |
| Suspended | Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic NCT05111561 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Soli NCT05269381 | Mayo Clinic | Phase 1 / Phase 2 |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumor NCT04514497 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fa NCT04673448 | University of Washington | Phase 1 |
| Recruiting | Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tu NCT04704661 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Pl NCT04585958 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma NCT04387071 | University of Southern California | Phase 1 / Phase 2 |
| Terminated | Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Sol NCT04800627 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Terminated | SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTI NCT04729725 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer NCT04294628 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without NCT04317105 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Active Not Recruiting | Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Pati NCT04197713 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Me NCT04068194 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Active Not Recruiting | Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors NCT04266912 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors NCT04007744 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydroch NCT03872427 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients W NCT03842228 | National Cancer Institute (NCI) | Phase 1 |
| Completed | ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors NCT03725436 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | SBRT-based PArtial Tumor Irradiation of HYpoxic Segment NCT04168320 | Klinikum Klagenfurt am Wörthersee | Phase 1 |
| Active Not Recruiting | Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma NCT03502733 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors NCT03030378 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer NCT02862275 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surg NCT02898207 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Rem NCT02595931 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for NCT02317874 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors NCT02079740 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer NCT01902173 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Active Not Recruiting | Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies NCT01364051 | National Cancer Institute (NCI) | Phase 1 |